186 related articles for article (PubMed ID: 21244767)
1. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.
Giordano N; Puccetti L; Papakostas P; Di Pietra N; Bruni F; Pasqui AL; Acampa M; Bocchi V; Donati V; Voglino M; Fioravanti A; Montella A; Auteri A; Nuti R; Pastorelli M
Int J Immunopathol Pharmacol; 2010; 23(4):1185-94. PubMed ID: 21244767
[TBL] [Abstract][Full Text] [Related]
2. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
[TBL] [Abstract][Full Text] [Related]
3. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
Cozzi F; Pigatto E; Rizzo M; Favaro M; Zanatta E; Cardarelli S; Riato L; Punzi L
Clin Rheumatol; 2013 May; 32(5):679-83. PubMed ID: 23344686
[TBL] [Abstract][Full Text] [Related]
4. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.
Humbert M; Cabane J
Rheumatology (Oxford); 2003 Jan; 42(1):191-3. PubMed ID: 12509640
[No Abstract] [Full Text] [Related]
6. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
[TBL] [Abstract][Full Text] [Related]
7. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
[TBL] [Abstract][Full Text] [Related]
8. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Nishibu A; Sakai E; Oyama N; Yamamoto T
Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
[TBL] [Abstract][Full Text] [Related]
9. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
[TBL] [Abstract][Full Text] [Related]
10. Bosentan in systemic sclerosis.
Heresi GA; Minai OA
Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
[TBL] [Abstract][Full Text] [Related]
11. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Shetty N; Derk CT
Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
[TBL] [Abstract][Full Text] [Related]
12. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.
Bellando-Randone S; Lepri G; Bruni C; Blagojevic J; Radicati A; Cometi L; De Paulis A; Matucci-Cerinic M; Guiducci S
Clin Rheumatol; 2016 Jan; 35(1):127-32. PubMed ID: 26631100
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension.
Opitz C; Klein-Weigel PF; Riemekasten G
Vasa; 2011 Jan; 40(1):20-30. PubMed ID: 21283970
[TBL] [Abstract][Full Text] [Related]
16. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
17. Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
Agard C; Carpentier PH; Mouthon L; Clerson P; Gressin V; Bérezné A; Diot E; Jego P; Lok C; Sparsa A; Chatelus E; Van Kien AK; Quéré I; Sibilia J; Hachulla E
Scand J Rheumatol; 2014; 43(5):398-402. PubMed ID: 24720440
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids.
Parisi S; Bruzzone M; Centanaro Di Vittorio C; Laganà A; Peroni CL; Fusaro E
Reumatismo; 2014 Mar; 65(6):286-91. PubMed ID: 24705032
[TBL] [Abstract][Full Text] [Related]
19. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
20. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
Launay D; Diot E; Pasquier E; Mouthon L; Boullanger N; Fain O; Jego P; Carpentier P; Hatron PY; Hachulla E
Presse Med; 2006 Apr; 35(4 Pt 1):587-92. PubMed ID: 16614599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
